Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 27

1.

Dominant-negative mutations in human IL6ST underlie hyper-IgE syndrome.

Béziat V, Tavernier SJ, Chen YH, Ma CS, Materna M, Laurence A, Staal J, Aschenbrenner D, Roels L, Worley L, Claes K, Gartner L, Kohn LA, De Bruyne M, Schmitz-Abe K, Charbonnier LM, Keles S, Nammour J, Vladikine N, Maglorius Renkilaraj MRL, Seeleuthner Y, Migaud M, Rosain J, Jeljeli M, Boisson B, Van Braeckel E, Rosenfeld JA, Dai H, Burrage LC, Murdock DR, Lambrecht BN, Avettand-Fenoel V, Vogel TP; Undiagnosed Diseases Network, Esther CR, Haskologlu S, Dogu F, Ciznar P, Boutboul D, Ouachée-Chardin M, Amourette J, Lebras MN, Gauvain C, Tcherakian C, Ikinciogullari A, Beyaert R, Abel L, Milner JD, Grimbacher B, Couderc LJ, Butte MJ, Freeman AF, Catherinot É, Fieschi C, Chatila TA, Tangye SG, Uhlig HH, Haerynck F, Casanova JL, Puel A.

J Exp Med. 2020 Jun 1;217(6). pii: e20191804. doi: 10.1084/jem.20191804.

PMID:
32207811
2.

Clinical relevance of pulmonary non-tuberculous mycobacterial isolates in three reference centres in Belgium: a multicentre retrospective analysis.

Vande Weygaerde Y, Cardinaels N, Bomans P, Chin T, Boelens J, André E, Van Braeckel E, Lorent N.

BMC Infect Dis. 2019 Dec 17;19(1):1061. doi: 10.1186/s12879-019-4683-y.

3.

Elexacaftor-Tezacaftor-Ivacaftor for Cystic Fibrosis with a Single Phe508del Allele.

Middleton PG, Mall MA, Dřevínek P, Lands LC, McKone EF, Polineni D, Ramsey BW, Taylor-Cousar JL, Tullis E, Vermeulen F, Marigowda G, McKee CM, Moskowitz SM, Nair N, Savage J, Simard C, Tian S, Waltz D, Xuan F, Rowe SM, Jain R; VX17-445-102 Study Group.

N Engl J Med. 2019 Nov 7;381(19):1809-1819. doi: 10.1056/NEJMoa1908639. Epub 2019 Oct 31.

PMID:
31697873
4.

Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial.

Heijerman HGM, McKone EF, Downey DG, Van Braeckel E, Rowe SM, Tullis E, Mall MA, Welter JJ, Ramsey BW, McKee CM, Marigowda G, Moskowitz SM, Waltz D, Sosnay PR, Simard C, Ahluwalia N, Xuan F, Zhang Y, Taylor-Cousar JL, McCoy KS; VX17-445-103 Trial Group.

Lancet. 2019 Nov 23;394(10212):1940-1948. doi: 10.1016/S0140-6736(19)32597-8. Epub 2019 Oct 31.

PMID:
31679946
5.

Prevalence and risk factors for Enterobacteriaceae in patients hospitalized with community-acquired pneumonia.

Villafuerte D, Aliberti S, Soni NJ, Faverio P, Marcos PJ, Wunderink RG, Rodriguez A, Sibila O, Sanz F, Martin-Loeches I, Menzella F, Reyes LF, Jankovic M, Spielmanns M, Restrepo MI; GLIMP Investigators.

Respirology. 2019 Aug 5. doi: 10.1111/resp.13663. [Epub ahead of print]

PMID:
31385399
6.

Prevalence and Etiology of Community-acquired Pneumonia in Immunocompromised Patients.

Di Pasquale MF, Sotgiu G, Gramegna A, Radovanovic D, Terraneo S, Reyes LF, Rupp J, González Del Castillo J, Blasi F, Aliberti S, Restrepo MI; GLIMP Investigators.

Clin Infect Dis. 2019 Apr 24;68(9):1482-1493. doi: 10.1093/cid/ciy723.

7.

CFTR activity is enhanced by the novel corrector GLPG2222, given with and without ivacaftor in two randomized trials.

Bell SC, Barry PJ, De Boeck K, Drevinek P, Elborn JS, Plant BJ, Minić P, Van Braeckel E, Verhulst S, Muller K, Kanters D, Bellaire S, de Kock H, Geller DE, Conrath K, Van de Steen O, van der Ent K.

J Cyst Fibros. 2019 Sep;18(5):700-707. doi: 10.1016/j.jcf.2019.04.014. Epub 2019 May 3.

8.

The nutritional status in CF: Being certain about the uncertainties.

Declercq D, Van Meerhaeghe S, Marchand S, Van Braeckel E, van Daele S, De Baets F, Van Biervliet S.

Clin Nutr ESPEN. 2019 Feb;29:15-21. doi: 10.1016/j.clnesp.2018.10.009. Epub 2018 Nov 7. Review.

PMID:
30661680
9.

An international perspective on hospitalized patients with viral community-acquired pneumonia.

Radovanovic D, Sotgiu G, Jankovic M, Mahesh PA, Marcos PJ, Abdalla MI, Di Pasquale MF, Gramegna A, Terraneo S, Blasi F, Santus P, Aliberti S, Reyes LF, Restrepo MI; GLIMP Study Group.

Eur J Intern Med. 2019 Feb;60:54-70. doi: 10.1016/j.ejim.2018.10.020. Epub 2018 Nov 4.

10.

VX-445-Tezacaftor-Ivacaftor in Patients with Cystic Fibrosis and One or Two Phe508del Alleles.

Keating D, Marigowda G, Burr L, Daines C, Mall MA, McKone EF, Ramsey BW, Rowe SM, Sass LA, Tullis E, McKee CM, Moskowitz SM, Robertson S, Savage J, Simard C, Van Goor F, Waltz D, Xuan F, Young T, Taylor-Cousar JL; VX16-445-001 Study Group.

N Engl J Med. 2018 Oct 25;379(17):1612-1620. doi: 10.1056/NEJMoa1807120. Epub 2018 Oct 18.

11.

Risk factors and impact of allergic bronchopulmonary aspergillosis in Pseudomonas aeruginosa-negative CF patients.

De Baets F, De Keyzer L, Van Daele S, Schelstraete P, Van Biervliet S, Van Braeckel E, Thomas M, Wanyama SS.

Pediatr Allergy Immunol. 2018 Nov;29(7):726-731. doi: 10.1111/pai.12953. Epub 2018 Aug 23.

PMID:
29981532
12.

Burden and risk factors for Pseudomonas aeruginosa community-acquired pneumonia: a multinational point prevalence study of hospitalised patients.

Restrepo MI, Babu BL, Reyes LF, Chalmers JD, Soni NJ, Sibila O, Faverio P, Cilloniz C, Rodriguez-Cintron W, Aliberti S; GLIMP.

Eur Respir J. 2018 Aug 9;52(2). pii: 1701190. doi: 10.1183/13993003.01190-2017. Print 2018 Aug.

13.

An unusual presentation of a case of human psittacosis.

Vande Weygaerde Y, Versteele C, Thijs E, De Spiegeleer A, Boelens J, Vanrompay D, Van Braeckel E, Vermaelen K.

Respir Med Case Rep. 2018 Feb 2;23:138-142. doi: 10.1016/j.rmcr.2018.01.010. eCollection 2018.

14.

Establishing the diagnosis of chronic colonization with Pseudomonas aeruginosa of cystic fibrosis patients: Comparison of the European consensus criteria with genotyping of P. aeruginosa isolates.

Jonckheere L, Schelstraete P, Van Simaey L, Van Braeckel E, Willekens J, Van Daele S, De Baets F, Vaneechoutte M.

J Cyst Fibros. 2018 Nov;17(6):729-735. doi: 10.1016/j.jcf.2018.03.004. Epub 2018 Apr 11.

PMID:
29655935
15.

Development and validation of an LC tandem MS assay for the quantification of β-lactam antibiotics in the sputum of cystic fibrosis patients.

Forier K, Van Heck V, Carlier M, Van Braeckel E, Van Daele S, De Baets F, Schelstraete P, Haerynck F, Stove V, Van Simaey L, Vaneechoutte M, Verstraete AG.

J Antimicrob Chemother. 2018 Jan 1;73(1):95-101. doi: 10.1093/jac/dkx331.

PMID:
29029070
16.

Sputum Neutrophil Elastase as a Biomarker for Disease Activity in Bronchiectasis.

Brusselle GG, Van Braeckel E.

Am J Respir Crit Care Med. 2017 May 15;195(10):1289-1291. doi: 10.1164/rccm.201612-2476ED. No abstract available.

PMID:
28504604
17.

Gastro-intestinal manifestations in cystic fibrosis patients.

Van Biervliet S, de Clercq C, Declercq D, Van Braeckel E, Van Daele S, De Baets F, De Looze D.

Acta Gastroenterol Belg. 2016 Sep-Dec;79(4):481-486. Review.

PMID:
28209107
18.

Global initiative for meticillin-resistant Staphylococcus aureus pneumonia (GLIMP): an international, observational cohort study.

Aliberti S, Reyes LF, Faverio P, Sotgiu G, Dore S, Rodriguez AH, Soni NJ, Restrepo MI; GLIMP investigators.

Lancet Infect Dis. 2016 Dec;16(12):1364-1376. doi: 10.1016/S1473-3099(16)30267-5. Epub 2016 Sep 1. Erratum in: Lancet Infect Dis. 2016 Dec;16(12):1324.

PMID:
27593581
19.

AZALEA Trial Highlights Antibiotic Overuse in Acute Asthma Attacks.

Brusselle GG, Van Braeckel E.

JAMA Intern Med. 2016 Nov 1;176(11):1637-1638. doi: 10.1001/jamainternmed.2016.6046. No abstract available.

PMID:
27653292
20.

Case report: a student of Asian origin with Pott's disease.

Roggeman S, Buyck G, Petrovic M, Callens S, Van Braeckel E.

Acta Clin Belg. 2016 Oct;71(5):340-342. doi: 10.1080/17843286.2016.1139318. Epub 2016 May 3.

PMID:
27141824

Supplemental Content

Loading ...
Support Center